The industry is in a difficult position. It is caught between wanting to satisfy the demands of the Trump administration while protecting its most important market and having minimal control over its negotiations with other countries. In other words, it is part stakeholder, participant and spectator.
Why not construct an off-ramp based on what you were going to do anyway?
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech -
US and EU secure new trade agreement, but 'more to come' on pharmaceuticals
July 28, 2025 - - Latest News -
Hepatitis Australia wants action as new analysis reveals many still missing cures
July 28, 2025 - - Latest News -
Ok for North Korea to have a say on our health responses, but not the US
July 28, 2025 - - Latest News -
Leading stakeholders call for urgency on national genomics framework
July 28, 2025 - - Latest News -
The Dispatched 'Week in Review' Podcast - 27 July
July 27, 2025 - - Podcast -
FDA invites submissions to new rapid review priority program
July 25, 2025 - - Latest News